Literature DB >> 24585566

Early warning indicators for HIV drug resistance in adults in South Africa at 2 pilot sites, 2008-2010.

Nomathemba M Dube1, Khin S Tint, Robert S Summers.   

Abstract

BACKGROUND: Approximately 5.2 million people in South Africa were infected with human immunodeficiency virus (HIV) by the year 2010, with just over 30% initiated on highly active antiretroviral therapy by 2011. With such numbers involved, the potential for the emergence of HIV drug resistance (HIVDR) is high. This study piloted early warning indicators (EWIs) for HIVDR at 2 clinics in South Africa.
METHODS: HIV-infected individuals aged ≥15 years and receiving antiretroviral drugs were enrolled into this cohort study between March 2008 and February 2010. All analyses were performed using the 2012 World Health Organization EWI score card.
RESULTS: A total of 1144 subjects were enrolled. Clinic A reached the target for 2 of the 5 EWIs but missed the desired target for on-time pill pickup, pharmacy stockouts, and virological suppression. Clinic B reached the target for 1 of 4 EWIs, namely, dispensing practices. Targets were missed for on-time pill pickup, retention in care, and virological suppression. Pharmacy stockouts could not be calculated at this site.
CONCLUSIONS: Actual performance against the levels that the pilot sites should reach to minimize HIVDR was low. Improvements in follow-up procedures, internal adherence support, monitoring for drug stockouts, and adherence are all aspects that need support to ensure that all records are complete. This pilot study may help to inform the South African government as EWI monitoring is implemented.

Entities:  

Keywords:  HIV; antiretroviral medicines; drug resistance; early warning indicators; pharmacovigilance

Mesh:

Substances:

Year:  2014        PMID: 24585566     DOI: 10.1093/cid/ciu109

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

1.  Outcomes of donor-derived superinfection screening in HIV-positive to HIV-positive kidney and liver transplantation: a multicentre, prospective, observational study.

Authors:  Tania S Bonny; Charles Kirby; Craig Martens; Rebecca Rose; Niraj Desai; Michael Seisa; Christos Petropoulos; Sander Florman; Rachel J Friedman-Moraco; Nicole A Turgeon; Diane Brown; Dorry L Segev; Christine M Durand; Aaron A R Tobian; Andrew D Redd
Journal:  Lancet HIV       Date:  2020-07-27       Impact factor: 12.767

Review 2.  Update on kidney transplantation in human immunodeficiency virus infected recipients.

Authors:  Khaled Nashar; Kalathil K Sureshkumar
Journal:  World J Nephrol       Date:  2016-07-06

3.  Challenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell count.

Authors:  Jean Joel R Bigna; Claudia S Plottel; Sinata Koulla-Shiro
Journal:  Infect Dis Poverty       Date:  2016-09-05       Impact factor: 4.520

Review 4.  Virological success after 12 and 24 months of antiretroviral therapy in sub-Saharan Africa: Comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis.

Authors:  Fabien Taieb; Yoann Madec; Amandine Cournil; Eric Delaporte
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

5.  Antiretroviral therapy related adverse effects: Can sub-Saharan Africa cope with the new "test and treat" policy of the World Health Organization?

Authors:  Jobert Richie N Nansseu; Jean Joel R Bigna
Journal:  Infect Dis Poverty       Date:  2017-02-15       Impact factor: 4.520

6.  Programme quality indicators of HIV drug resistance among adolescents in urban versus rural settings of the centre region of Cameroon.

Authors:  Joseph Fokam; Armanda Nangmo; Carlson Wandum; Desire Takou; Maria Mercedes Santoro; Anne-Esther Njom Nlend; Francis Ndongo Ateba; Paul Koki Ndombo; Nelly Kamgaing; Cedric Kamta; Andre Essiane; Virginie Lambo; Charles Fokunang; Dora Mbanya; Vittorio Colizzi; Carlo-Federico Perno; Alexis Ndjolo
Journal:  AIDS Res Ther       Date:  2020-05-12       Impact factor: 2.250

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.